Carol Tamminga

Professor & Chairman, Department of Psychiatry at The University of Texas - Southwestern Medical Center

Carol Tamminga

Carol Tamminga

Professor & Chairman, Department of Psychiatry at The University of Texas - Southwestern Medical Center

Overview
Career Highlights

The American College of Neuropsychopharmacology, Inc.

RelSci Relationships

1185

Number of Boards

1

Relationships
RelSci Relationships are individuals Carol Tamminga likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Intra-Cellular Therapies, Inc.

Relationship likelihood: Strong

Chairman-Molecular Biology Department at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Vice President-Business Development at ITI, Inc. - New York

Relationship likelihood: Strong

President at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Vice Provost & Dean of Basic Research at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Executive Vice President for Academic Affairs & Provost at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Lisa K. Simmons Distinguished Chair in Comprehensive Oncology at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Philip O'Bryan Montgomery Junior, MD, Distinguished Chair in Developmental Biology at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Mary McDermott Cook Chair, Pediatric Genetics at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Chairman, Department of Developmental Biology at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Paths to Carol Tamminga
Potential Connections via
Relationship Science
You
Carol Tamminga
Professor & Chairman, Department of Psychiatry at The University of Texas - Southwestern Medical Center
Education
MD Unknown

Vanderbilt University School of Medicine is a medical school located in Nashville, Tennessee. Currently tied for 14th on the list of accredited medical schools in the U.S News & World Report 2016 rankings, the school of medicine has a reputation as a center of research and high-quality clinical care. Vanderbilt School of Medicine is ranked No. 10 among U.S. medical schools for funding from the National Institutes of Health. Located in the Vanderbilt University Medical Center on the southeastern side of the Vanderbilt University campus, the School of Medicine claims two Nobel laureates: Earl W. Sutherland Jr., in 1971, for his discovery of the metabolic regulating compound cyclic AMP, and Stanley Cohen, in 1986, for his discovery with a colleague of epidermal growth factor.

Career History
Professor & Chairman, Department of Psychiatry
Current

UT Southwestern Medical Center is distinctive for its overall quality and for the strength of its three core missions of education, research, and patient care. These mission components are highly interdependent; each is integral to and enhances the others.UT Southwestern consists today of three degree-granting schools and a University Health System of hospitals and clinics. Its faculty is renowned for including six Nobel Laureates (one now Emeritus) and many members of the National Academy of Sciences and Institute of Medicine, and UT Southwestern Medical Center is either nationally ranked or rated as high performing in nearly a dozen specialties by U.S. News & World Report.

Clinical & Scientific Advisor
Current

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Member, Schizophrenia Research Team
Tenure Unconfirmed

NIH is the largest source of funding for medical research in the world, creating hundreds of thousands of high-quality jobs by funding thousands of scientists in universities and research institutions in every state across America and around the globe. NIH is made up of 27 Institutes and Centers, each with a specific research agenda, often focusing on particular diseases or body systems. NIH leadership plays an active role in shaping the agency's research planning, activities, and outlook. The Office of the Director is the central office at NIH, responsible for setting policy for NIH and for planning, managing, and coordinating the programs and activities of all the NIH components. The NIH Director, with a unique and critical perspective on the entire agency, is responsible for providing leadership to the Institutes and for constantly identifying needs and opportunities, especially for efforts that involve multiple Institutes. The NIH Director is assisted by the NIH Deputy Directors including the Principal Deputy Director, who shares in the overall direction of the agency's activities. NIH is responsive to Congressional legislation that adjusts NIH's programs to meet changing research needs. As a result of the NIH reauthorization process, NIH is able to respond strategically in an era when medical research requires constant innovation and increased interdisciplinary efforts. More than 80% of the NIH's budget goes to more than 300,000 research personnel at over 2,500 universities and research institutions. In addition, about 6,000 scientists work in NIH’s own Intramural Research laboratories, most of which are on the NIH main campus in Bethesda, Maryland. The main campus is also home to the NIH Clinical Center, the largest hospital in the world totally dedicated to clinical research. Successful biomedical research depends on the talent and dedication of the scientific workforce. NIH supports many innovative training programs and funding mechanisms that foster scientific creativity and exploration. The goal is to strengthen our nation’s research capacity, broaden our research base, and inspire a passion for science in current and future generations of researchers. NIH encourages and depends on public involvement in federally supported research and activities. NIH’s wide-ranging public efforts include outreach and education, nationwide events, requests for public input on NIH projects, and special programs designed specifically to involve public representatives in clinical research

Boards & Committees
Chair, Medical Advisory Board
Current

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Carol Tamminga. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Carol Tamminga's profile does not indicate a business or promotional relationship of any kind between RelSci and Carol Tamminga.